NVAX
NOVAVAX INC
NASDAQ · Healthcare · Biotechnology · US
$10.32
+6.59%Forward multiples
Based on analyst estimates
- P/E forward
- 60.33x
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 34.71x
- P/S forward
- 3.48x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -8.92x
- Price / sales
- 4.11x
- Price / cash flow
- -43.09x
Enterprise value
- Enterprise value
- $1.3B
- EV / sales
- 3.09x
- EV / EBITDA
- -6.22x
- EV / EBIT
- -5.62x
- Market cap
- $1.7B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026